The kratom product landscape has changed dramatically over the last few years. A decade ago, “kratom” in the United States meant leaf powder or capsules — dried Mitragyna speciosa sold as a botanical supplement. Today, the fastest-growing kratom category at smoke shops, gas stations, and online retailers is concentrated 7-hydroxymitragynine — tablets, gummies, lozenges, and liquid shots that contain far more 7-OH than the plant naturally produces. This distinction is the single most important thing to understand if you’re weighing your own use or helping someone else.
The Botany: Kratom Contains 50+ Alkaloids
Kratom (Mitragyna speciosa) is a tropical tree in the coffee family, native to Southeast Asia. Its leaves contain more than 50 alkaloids — plant-derived compounds with biological effects — but only two matter much clinically: mitragynine and 7-hydroxymitragynine (7-OH). Both act on the mu-opioid receptor in the brain, which is the same receptor targeted by prescription opioids, heroin, and fentanyl. That shared mechanism is why kratom produces opioid-like effects and why regular use can cause opioid-type physical dependence and withdrawal.
Mitragynine is the most abundant alkaloid in the leaf — usually around 1-2% of dry leaf weight. 7-OH is present too, but in very small amounts — typically under 0.05% of dry leaf weight, sometimes as a fresh-leaf metabolite or produced in small quantities during drying. In whole-leaf kratom, mitragynine is doing most of the work, and the slower onset + broader alkaloid mix tends to produce milder effects than a pure opioid would.
Why 7-OH Matters Disproportionately to Its Amount
Here’s the pharmacology wrinkle: despite making up a tiny fraction of total alkaloids, 7-OH is a substantially more potent mu-opioid agonist than mitragynine. Lab studies in animal models suggest 7-OH binds more tightly and activates the receptor more strongly. The FDA, in its July 2025 assessment, specifically cited animal studies showing dependence and abuse potential consistent with classical opioids.
In unprocessed leaf, 7-OH’s potency is moderated by the tiny quantities present and by mitragynine’s more dampening effect profile. Strip 7-OH out of the leaf and concentrate it alone — as a tablet, a gummy, a shot — and the pharmacology changes categorically. A product that delivers pure 7-OH at milligram or multi-milligram doses is no longer behaving like leaf kratom. It’s behaving like a concentrated opioid agonist.
How Concentrated 7-OH Products Are Made
Manufacturers extract and isolate 7-OH using standard chemistry methods — solvent extraction, purification, and recrystallization — to create products with 7-OH content that can be hundreds of times higher per gram than whole leaf. Some products are described on the label as containing specific milligram amounts of 7-OH per serving, or multiples of “1x/2x/5x extract,” though labeling accuracy in the unregulated market is notoriously inconsistent.
A few kratom industry groups and some state regulators have specifically flagged concentrated 7-OH products as outside the traditional kratom market, arguing that a whole-leaf regulatory framework should not cover them. The FDA, from the other direction, has singled out concentrated 7-OH for Schedule I scheduling precisely because it’s pharmacologically different from whole leaf. Both positions agree on the core point: concentrated 7-OH is not the same substance as the traditional product.
Why Withdrawal from 7-OH Concentrates Is Harder
Patients dependent on concentrated 7-OH products consistently describe withdrawal that is more intense and more relapse-prone than withdrawal from whole-leaf kratom. The pharmacology is consistent with that experience:
- Deeper tolerance. Regular high-dose exposure to a strong mu-agonist produces more receptor adaptation than exposure to a milder, mixed-alkaloid profile. The gap during withdrawal is correspondingly steeper.
- Faster onset of withdrawal. Concentrated 7-OH is typically dosed multiple times per day because of its shorter duration of effect. That dosing rhythm means blood levels rise and fall frequently — and withdrawal can begin within hours of a missed dose.
- More severe anxiety, insomnia, and cravings. Reported frequently enough that it’s useful for clinicians to plan for it specifically. The first week after stopping 7-OH concentrates is often described by patients as the hardest week of their lives.
- Quicker rebound on re-exposure. Because the product is fast-onset and high-potency, a single use after a partial taper often resets the cycle completely. This is why clinicians generally recommend MAT over self-taper for 7-OH dependence.
For a day-by-day picture of what the withdrawal arc typically looks like, see our article on the kratom withdrawal timeline. The mechanisms described there apply to both leaf and 7-OH, but the intensity on the 7-OH side is typically worse.
The FDA’s July 2025 Action: What It Actually Targets
On July 29, 2025, the FDA formally recommended to the DEA that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act. Two weeks earlier, on July 15, the FDA had issued warning letters to seven companies marketing 7-OH products (Shaman Botanicals, My Smoke Wholesale, RRR Trading / EDP Kratom, Thang Botanicals / 7ΩHMZ, Royal Diamond Imports / Roxytabs, Hydroxie LLC, and 7Tabz Retail), citing unapproved new drug claims and misbranding.
Three things about this are important to understand:
- The scope is narrow. The FDA recommendation applies to concentrated 7-OH products — tablets, gummies, drink mixes, shots, and similar. Natural whole-leaf kratom was not targeted by the Schedule I recommendation.
- It’s a recommendation, not law. The DEA reviews FDA recommendations and goes through its own rulemaking process, which includes a public-comment period, before any final scheduling action. This can take months to years.
- The DEA had already flagged both substances. On January 22, 2025, the DEA formally designated kratom and 7-hydroxymitragynine as Drugs of Concern — a classification that signals potential for abuse without scheduling the substance. The July 2025 FDA recommendation adds pressure toward formal scheduling of the concentrate-only subset.
At the state level, Tennessee has two bills pending that would approach the same problem differently: HB1647 (criminalize kratom broadly) and HB2594 (regulate kratom with a cap of 2% 7-OH or 1 mg per serving). See our Tennessee kratom laws article for the detailed picture on that front.
What This Means If You’re Using Concentrated 7-OH
The regulatory wave is one reason to consider stopping, but it’s not the most important one. The more compelling reason is the health picture: concentrated 7-OH is producing opioid-type dependence severe enough that the Tennessee Department of Health now reports withdrawal as the #1 reason Tennesseans visit the emergency room after using kratom (30.4% of kratom ER visits, up sharply in 2025). Kratom-involved ER visits in Tennessee doubled from 2024 to 2025 (77 → 153), and the fastest-growing segment is men and adults 18–44 — the demographic most likely to be using concentrates.
If any of the following describe your use, the clinical case for seeking treatment is strong:
- You’ve escalated from lower-potency products to 7-OH tablets, gummies, or shots.
- You’re dosing multiple times per day to avoid early withdrawal.
- You’ve tried to stop and returned to use within days.
- Product availability (particular brand, particular dose) is shaping your day.
- You’ve experienced withdrawal symptoms that surprised you — aches, anxiety, GI distress, insomnia within hours of skipping a dose.
Treatment Works the Same Way It Does for Leaf Kratom
The same medication-assisted treatment that works for whole-leaf kratom dependence works for concentrated 7-OH dependence — because the underlying mechanism is the same mu-opioid receptor adaptation. Suboxone (daily sublingual), Sublocade (monthly injection), and Brixadi (weekly/bi-weekly/monthly injection) are all buprenorphine-based and clinically appropriate for 7-OH-type dependence.
What differs for 7-OH patients is often the intake timing — our providers plan the induction window carefully because abrupt transitions from high-potency concentrate to buprenorphine can trigger precipitated withdrawal if the timing is off. For the clinical details on how MAT handles kratom and 7-OH withdrawal, see our article on Suboxone for kratom withdrawal.
What to Do Next
If you or someone you care about is using concentrated 7-OH products and finding it hard to stop, call 423-498-2000 or submit a contact request. Same-week appointments are available at all four of our clinic locations across Tennessee and Georgia. The regulatory picture will keep shifting over the next year or two, but the treatment path is stable and works.